SCHEMBL6479703

SCHEMBL6479703

O=S(=O)(Nc1cccc(CCOCc2cccc(-c3ccc(F)cc3)c2)c1)C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.45
AGXT P21549 2/20 0.44
MGLL Q99685 2/20 0.41
CA2 P00918 2/20 0.40
PRMT6 Q96LA8 1/20 0.40
CYSLTR2 Q9NS75 2/20 0.39
CYSLTR1 Q9Y271 2/20 0.39
KIF11 P52732 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.36
PTPN5 P54829 1/20 0.36
NAAA Q02083 1/20 0.36
RORC P51449 1/20 0.36
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
CNR1 P21554 1/20 0.36
ASAH1 Q13510 1/20 0.36
CA1 P00915 1/20 0.35
PFKFB3 Q16875 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6479679 0.94 KDM1A (0.42) KDM1AAGXTMGLLCA2PRMT6
SCHEMBL6481112 0.89 KDM1A (0.41) KDM1AAGXTMGLLCA2PRMT6
SCHEMBL6479426 0.89 KDM1A (0.43) KDM1ACA2PRMT6CYSLTR2CYSLTR1
SCHEMBL6474945 0.87 KDM1A (0.39) KDM1AAGXTMGLLCA2PRMT6
SCHEMBL6475101 0.86 KDM1A (0.40) KDM1ACA2PRMT6CYSLTR2CYSLTR1
SCHEMBL6482194 0.85 KDM1A (0.43) KDM1AMGLLCA2PRMT6CYSLTR2
SCHEMBL6474331 0.85 ERAP1 (0.38) KDM1AMGLLCA2PRMT6CYSLTR2
SCHEMBL6483863 0.84 PPARA (0.47) KDM1ACA2PRMT6CYSLTR2CYSLTR1
SCHEMBL6482520 0.84 KIF11 (0.46) KDM1AAGXTMGLLCA2CYSLTR2
SCHEMBL6474738 0.84 CYSLTR2 (0.46) KDM1ACA2PRMT6CYSLTR2CYSLTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930131-B2 Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) WYETH (US) 2005-08-16 US disclosed
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus GPR119, INSR, SLC5A1 KDM1A 1124/4885AGXT 182/4885MGLL 2631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.